This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Nuvectra Corp. (neuromodulation devices) netted $64.9mm in a public offering of 3.2mm shares (including the overallotment) at $21.25. The company will use the proceeds to expand product development and commercialization. Nuvectra is awaiting CE Mark and PMA approval for its Virtis sacral nerve stimulation (SNS) device for urinary incontinence and overactive bladder. In July, both EU and US agencies informed Nuvectra that additional clinical study data would be required before recommending approval, but the company still anticipates product launches by the end of the year (EU) and during 1H 2019 (US).
Already a Strategic Transactions subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?